# Code Log

## Commands Run

```bash
checkpoint status
sed -n '1,240p' .march/ticket.md
sed -n '1,260p' .march/design-draft.md
sed -n '1,260p' .march/design-final.md
sed -n '1,260p' spec/05-drug.md
sed -n '1,140p' Makefile
env -u BIOMCP_EMA_DIR XDG_DATA_HOME="$(mktemp -d)" XDG_CACHE_HOME="$(mktemp -d)" ./target/release/biomcp search drug pembrolizumab --limit 3
env -u BIOMCP_EMA_DIR XDG_DATA_HOME="$(mktemp -d)" XDG_CACHE_HOME="$(mktemp -d)" ./target/release/biomcp search drug pembrolizumab --region us --limit 3
PATH="$PWD/target/release:$PATH" uv run --extra dev pytest spec/05-drug.md --collect-only -q
PATH="$PWD/target/release:$PATH" uv run --extra dev pytest spec/05-drug.md -k 'Searching and Name' --mustmatch-lang bash --mustmatch-timeout 60 -v
PATH="$PWD/target/release:$PATH" uv run --extra dev pytest spec/05-drug.md -k 'Search and Help and Shows and Region and Defaults' --mustmatch-lang bash --mustmatch-timeout 60 -v
PATH="$PWD/target/release:$PATH" uv run --extra dev pytest spec/05-drug.md -k 'EMA and Search and Region or Default and Drug and Search and Covers and US and EU or EMA and Search and All and Regions or EMA and Regulatory and Section or EMA and Safety and Truthful and Empty and Sections or EMA and Shortage and Section' --mustmatch-lang bash --mustmatch-timeout 60 -v
env -u BIOMCP_EMA_DIR XDG_DATA_HOME="$(mktemp -d)" make spec-pr
make check
git status --short
git diff -- spec/05-drug.md .march/checkpoint.json .march/code-log.md
checkpoint done 1
checkpoint note "Approved design keeps CI topology unchanged; repair spec/05-drug.md::Searching by Name to use --region us so spec-pr stays EMA-independent."
checkpoint note "Proof updated in spec/05-drug.md; stable clean-environment search uses --region us and the remaining EMA sections still pass via fixture-backed markdown specs. Markdown spec selection needed pytest -k filters because direct file.md::Heading selection does not resolve in this repo."
checkpoint note "make spec-pr passed with BIOMCP_EMA_DIR unset and a fresh XDG_DATA_HOME: 208 passed, 6 skipped, 36 deselected. make check also passed after the spec update."
checkpoint done 2
checkpoint done 3
```

## What Changed

- Updated [spec/05-drug.md](/home/ian/workspace/worktrees/056-ci-ema-spec-lane/spec/05-drug.md) so the stable `Searching by Name` section now uses `biomcp search drug pembrolizumab --region us --limit 3`.
- Adjusted the summary table in [spec/05-drug.md](/home/ian/workspace/worktrees/056-ci-ema-spec-lane/spec/05-drug.md) to document the U.S.-only stable proof instead of the hidden all-regions path.
- Rewrote the `Searching by Name` prose in [spec/05-drug.md](/home/ian/workspace/worktrees/056-ci-ema-spec-lane/spec/05-drug.md) to make the contract explicit: the PR gate covers stable U.S. lookup there, while later fixture-backed sections continue to cover the no-flag U.S.+EU default and explicit EMA regions.
- Left `Makefile`, workflows, and runtime code unchanged, per the approved final design.

## Tests And Proof Added/Updated

- Updated the markdown spec proof in [spec/05-drug.md](/home/ian/workspace/worktrees/056-ci-ema-spec-lane/spec/05-drug.md) instead of adding a new code-level test, because the final design scoped the fix to the stable spec contract.
- Captured the pre-change behavior with a clean-environment CLI probe:
  - `search drug pembrolizumab --limit 3` created an EMA data root and emitted `Downloading EMA data`.
- Captured the intended behavior with a matching clean-environment CLI probe:
  - `search drug pembrolizumab --region us --limit 3` succeeded with the expected heading/table and no EMA directory creation or download message.
- Verified the updated stable section and adjacent contract coverage with focused markdown-spec runs:
  - `Searching by Name`
  - `Search Help Shows Region Defaults`
  - `EMA Search Region`
  - `Default Drug Search Covers US and EU`
  - `EMA Search All Regions`
  - `EMA Regulatory Section`
  - `EMA Safety Truthful Empty Sections`
  - `EMA Shortage Section`

## Verification Results

- Passed clean-environment CLI proof for `biomcp search drug pembrolizumab --region us --limit 3` with no EMA side effects.
- Passed `PATH="$PWD/target/release:$PATH" uv run --extra dev pytest spec/05-drug.md -k 'Searching and Name' --mustmatch-lang bash --mustmatch-timeout 60 -v`.
- Passed `PATH="$PWD/target/release:$PATH" uv run --extra dev pytest spec/05-drug.md -k 'Search and Help and Shows and Region and Defaults' --mustmatch-lang bash --mustmatch-timeout 60 -v`.
- Passed `PATH="$PWD/target/release:$PATH" uv run --extra dev pytest spec/05-drug.md -k 'EMA and Search and Region or Default and Drug and Search and Covers and US and EU or EMA and Search and All and Regions or EMA and Regulatory and Section or EMA and Safety and Truthful and Empty and Sections or EMA and Shortage and Section' --mustmatch-lang bash --mustmatch-timeout 60 -v`.
- Passed `env -u BIOMCP_EMA_DIR XDG_DATA_HOME="$(mktemp -d)" make spec-pr` with `208 passed, 6 skipped, 36 deselected`.
- Passed `make check`.

## Deviations

- The approved final design superseded the draft design. No `Makefile` or workflow changes were made.
- The proof matrix in the design used `pytest spec/file.md::Heading` examples, but this repo's markdown collector did not resolve those selectors directly. Verification used `pytest spec/05-drug.md -k ...` filters against the collected `BashItem` headings instead.
